Mexico to rely heavily on Chinese vaccines

Mexico has just made a huge bet on Chinese vaccines, without making public any information about their efficacy

Virus Outbreak Mexico
Virus Outbreak Mexico

Mexico announced a huge bet on Chinese vaccines Tuesday, without making public any information about their efficacy.

Foreign Relations Secretary Marcelo Ebrard said the Mexican government has signed agreements for 12 million doses of the yet-unapproved Sinopharm vaccine and increased to a total of 20 million doses its contracts for the Coronavac dose made by China’s Sinovac

Deliveries of Sinovac have already started, with the full 20 million doses expected by July. The Sinopharm vaccines are to be delivered between March and June.

The total of 32 million doses, plus at least 4 million doses of the CanSino shot, would dwarf the estimated 5 million vaccine doses Mexico has acquired so far from other sources.

However, Ebrard’s office has repeatedly refused to answer questions about the efficacy of the Chinese shots.

Sinopharm has claimed its vaccine was 79% effective based on interim data from clinical trials, but like other Chinese firms, it has not publicly released its late-stage clinical trial data.

Experts in Hong Kong have assessed the efficacy of the Sinovac vaccine at about 51%. That shot has already been approved for use in Mexico.

The CanSino vaccine has been approved in Mexico and reportedly has an efficacy rate of around 65.7%,

A total of six vaccines have been approved for use in Mexico, which has received relatively small amounts of each. Mexico has administered only about 4.7 million doses of all vaccines, a tiny amount given the country’s population of 126 million.

The government policy sets up the odd situation in which some Mexicans, mainly in urban areas, will receive the Pfizer vaccine, which has around 95% efficacy, while most will get one of the Chinese vaccines with a much lower effectiveness. Mexico has contracts for a total of about 34 million doses of the Pfizer shot, but deliveries have been slow, with less than a tenth of that amount delivered so far.

Amid a dearth of public data on China’s vaccines, hesitations over their efficacy and safety are still pervasive in the countries depending on them.

Inoculations with Chinese vaccines already have begun in more than 25 countries. None of China’s three vaccine candidates used globally have publicly released their late-stage clinical trial data.

Mexico has suffered almost 190,100 confirmed deaths. However, Mexico does so little testing that government excess-death figures suggest the real toll was well above 220,000 at the start of January, when the government stopped releasing that data. Test-confirmed cases total over 2.1 million.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in